The Future Of Allogeneic Hematopoietic Stem Cell Transplantation For Metastatic Renal Cell Carcinoma In The Era Of Target-Specific Therapy

... UroToday.com - Allogeneic hematopoietic stem cell transplantation (BMT) for metastatic renal cell carcinoma (RCC) was first reported by Childs in 1999. In that report, patients received a conditioning regimen of fludarabine/cyclophosphamide, prior to BMT. The incidence of acute graft versus host disease (GVHD, thought to be linked to tumor response) was 53% and chronic GVHD was 21%. [click link for full article] ...